Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.

@article{Zlotta1994EvolutionOC,
  title={Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.},
  author={Alexandre R. Zlotta and Annie Drowart and J-P Van Vooren and J. Simon and Claude C. Schulman and Kris Huygen},
  journal={Acta urologica Belgica},
  year={1994},
  volume={62 3},
  pages={63-8}
}
Prophylactic treatment with Bacillus Calmette-Guerin (BCG) is an established and effective therapy of bladder cancer. The antitumor effect of BCG seems to be largely related to cellular immunological mechanisms, although its precise mode of action is unknown. Antitumor response of BCG seems to be initiated by the attachment of BCG to bladder wall via Fibronectin (FN). The cellular immune response against Tuberculin PPD and the major secreted BCG antigen (Fibronectin-binding AG 85 complex) has… CONTINUE READING